# OCTOBER 2017



#### In This Issue

- 1. APHA Annual Meeting and Exposition
- 2. Breakthrough Drugs
- 3. Generic Approvals in the Works
- 4. Industry News



APHA Annual meeting March 16 - 19 2018 Nashville TN

### breakthrough Drugs

- Solosec [ treatment of bacterial vaginosis] Approved 9/15/17
- Vabomere [treatment of adult complicated urinary tract infection] Approved 8/29/17
- Verzenio [ treatment of advanced or metastatic breast cancer] Approved 9/28/17.
- Benznidazole [ treatment of 2 to 12 year olds with chagas disease] Approved 08/29/17







## Generic approvals in the works

Factive (March 2018)

Vesicare (October 2018)

Adcirca (November 2017)

Treximet (February 2018)

Lyrica (December 2018)

Ranexa (February 2019)



NDC 10122-321-05

Unit-of-Use Package

Take one tablet daily.

closed Medication Guide is to be dispersed to patients.

fach tablet contains gemiffesacin mesylate equivalent to 320 mg gemiffesacin.

5 Tablets

DAYS OF THERAPY

CORNERSTONE









### Industry News

Drug Shortages: Have been recorded for over 15 years. However recent shortages of common drugs like atenolol and nature -throid should be cause for concern. Reasons for the scarcity of these drugs may be due to

- Manufacturing difficulties
- Raw material shortages - Recalls
- Business stresses
- Natural disasters: Hurricane Maria devastated the lives of the people on the Island of Puerto Rico. With about 94% of the island [including approximately 50 Pharmaceutical Companies] still without electricity, drugs cannot be produced and employees cannot safely navigate through the treacherous roads to get to work.



Caption



#### References

1)https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040.htm 2)https://twitter.com/campha\_usa